Dennis Fenton has been nominated for election to the board of directors at Genzyme. Fenton worked at Amgen for 25 years culminating in him holding the position of executive vice president (EVP) of operations.
Biologics manufacturing experience gained at Amgen was a key factor in Fenton’s nomination. The move fulfils Genzyme’s commitment to nominate an independent director recommended by Relational Investors with substantial biopharm manufacturing experience.
The board of directors at Elan Pharmaceuticals and Kelly Martin, the company’s CEO, have agreed to change his contract from an open-ended agreement to a fixed term deal.
Martin will now work as CEO and director until May 1 2012. After this Martin will take the post of executive advisor until January 31 2013. Having completed his tenure as executive advisor Martin will leave the company, ending his 10 year involvement.
Renaat Van den Hooff has resigned as president and CEO of drug delivery specialist Uluru. Kerry Gray has been appointed the board of directors and will replace Van den Hooff as president and CEO.
Jazz Pharmaceuticals has appointed Paul Berns to its board of directors. Berns has worked at Allos Therapeutics, Bone Care, Abbott Laboratories and BASF Pharmaceuticals-Knoll.
Lawrence Kenyon has resigned as EVP and chief financial officer of Par Pharmaceuticals to pursue other opportunities. Kenyon will be replaced by Michael Tropiano who joined the company in 2005 as VP and treasurer.
Glenmark Pharmaceuticals has named Penelope Ward as president, clinical research and development and chief medical officer. Ward has previously worked at Pharmacia & Upjohn, GlaxoSmithKline and Roche.